CEO Kevin Lobo is optimistic about the company's growth trajectory, aiming for 10% organic growth in Q4. CFO Glenn Boehnlein highlights cost-saving initiatives driving margin expansion. Strong international hip sales are fueled by product innovation, with positive early feedback on Mako Spine.